Europe must act to restore biotech competitiveness, industry warns
Episode details
Episode description
In this interview, Olaf Weppner, Vice President for Europe Region North at AbbVie, discusses the company’s footprint in Europe and the broader challenges shaping the region’s biotech sector. He highlights Europe’s strong scientific base, skilled workforce, and research infrastructure, while pointing to a decline in global competitiveness, including reduced clinical trial activity and increasing competition from other regions. The discussion explores the evolving EU policy landscape, including the Biotech Act, the General Pharmaceutical Legislation, and the Critical Medicines Act, and their implications for innovation, investment, and patient access. Olaf Weppner emphasises the importance of a more integrated and predictable regulatory framework, as well as the role of pricing, reimbursement, and cross-sector policy coherence in strengthening Europe’s life sciences ecosystem. He also reflects on expectations for the Irish Council Presidency and its potential to drive momentum on competitiveness and access to innovation. For more EU news, visit our webpage: https://www.euractiv.com/ Follow us on Social Media X: https://x.com/Euractiv Facebook: https://www.facebook.com/EURACTIV Instagram: https://www.instagram.com/euractiv/